Head-to-head evidence
Inbrija (CVT-301) vs ND0612
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Inbrija (CVT-301)
Marketed by Merz Therapeutics
NCT02240030 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 351 participants and a clinical primary endpoint based on the UPDRS Part III motor score. Although the primary score numerically favored high-dose CVT-301 over placebo, the registry does not state whether that primary comparison was statistically significant, so the result remains unclear.
ND0612
Developed by NeuroDerm Ltd.
NCT02577523 · Phase 2 · completed
Participants were randomized to two ND0612 regimens, but the study was only single-blinded for outcome assessors, had no placebo or active-control arm, and was small with 19 participants per group. The clinical primary endpoint was daily OFF time; although the 24-hour regimen showed a numerically greater reduction, statistical significance for the comparison was not reported, so the result is unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inbrija (CVT-301)'s landscape · ND0612's landscape